Drug intelligence / Profile preview

GEN1504

Development stage: Unknown
Lead developer: GeneSys Biologics
Administration: Subcutaneous

Overview

GEN1504 is a biosimilar of Humalog (lispro insulin), developed by GeneSys Biologics Pvt Ltd. It is intended for the treatment of diabetes mellitus, specifically targeting endocrinology and metabolic diseases. The drug's mechanism involves mimicking the action of natural insulin to regulate blood glucose levels.

Other names: lispro insulin-GEN1504Humalog biosimilar

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on GEN1504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GEN1504.

Explore the full profile